No one doubts the importance of insects as vectors of disease. They are being especially marked out for attention this year with Vector Borne Disease being the focus of World Health Day on April 7th and just a few weeks later on April 25th World Malaria day will be observed. With all this emphasis on vector borne disease it seems appropriate to reflect on the contribution of insecticides in vector control and where the future might take us.
In the 30 years since I started my involvement with the development and marketing of public health insecticide products many breakthroughs have made significant impacts on reducing the burden of vector borne diseases. One such breakthrough was the development of insecticide treated bed nets. In the early 1980s studies had demonstrated that adding a pyrethroid insecticide to a bed net significantly doubled its protective efficacy with the repellent action of the pyrethroid allowing the net to continue working even when holed. If a community were given treated nets then a mass effect resulted, reducing mosquito biting pressure and affording a degree of protection even to those not sleeping under a net. These early nets had to be dipped in insecticide at 6 monthly intervals, as repeated washing and use removed the surface deposit. The logistics of the necessary massive retreatment campaigns limited the spread and adoption of this life saving intervention. The paradigm shift came with the invention of long lasting nets where the insecticide was either incorporated into the net fibre, or coated onto the fibre with a binder. These so called long lasting insecticide treated nets or LNs could withstand multiple washings and provide protection for 3 or more years. This innovation was a major boost to the adoption of treated nets and today close to 1 billion LNs have been manufactured and distributed, mainly in sub Saharan Africa where the burden of malaria is greatest. The issue of determining how many deaths and cases of malaria LNs have avoided is, of course, highly complex. Lengeler has estimated that approximately 5.5 lives could be saved per year for every 1000 children under 5 years of age protected. Making a broad assumption that the nets so far distributed may have provided an average of 2 years protection (some will have only been in use for a year, others will have become worn out after less than 3 years and others will have lasted 4-5 years) and assuming that 20-30% of nets are slept under by young children, these LNs have reduced childhood malaria deaths by around 3 million -an achievement of which the insecticide industry and other stakeholders can be truly proud.
Malaria is still responsible for 200 million debilitating cases and over 600 thousand deaths a year, so while the battle is still a long way from being won, there is no doubt that vector control -when done properly -is a highly effective way of reducing disease burden, not just for malaria but for other vector borne diseases such as Leishmaniasis, Chagas disease and onchocerciasis. In the case of Dengue and Dengue Haemorrhagic Fever the number of cases have increased dramatically with increased urbanisation, from an average of 295,000 cases in 1980-1989 to 926,000 cases in 2000 -2007 (WHO, 2009 . With a really effective vaccine still many years away vector control remains an important component in dengue control programmes. In addition, climate change and increased global travel have enabled diseases like Chikungunya and West Nile virus to continue to spread and with no vaccine available for either disease vector control is, here again, an important tool in mitigating impact.
Despite the importance of insecticides in the control of vector borne diseases, there are only 4 chemical classes of adulticides currently recommended for use by the World Health Pesticide Evaluation Scheme (WHOPES)*: organochlorines, organophosphates, carbamates and pyrethroids. Resistance to all these classes of chemistry is spreading in malaria vectors across Africa. Resistance is also a serious problem in the vectors of many other insect borne diseases. There is a real concern that resistance may result in operational failure and a subsequent rise in the number of cases and deaths of malaria and other vector borne diseases. Surprisingly then there have been no new classes of adulticide chemistry introduced through the WHOPES system in the last 40 years -and no new adulticides at all in over 20 years. We clearly need new insecticides, but the relative size of the vector control market is tiny -a mere 2% of the size of the global chemical crop and non crop market.
It has been estimated that the costs of developing a single new pesticide active ingredient for agricultural use is over $250 million (Phillips MacDougall, 2013) . The cost of developing an insecticide specifically for the vector control market will be less than this (for example there is no need to develop residue limits, as vector control products are not intended for direct application to food) but costs are still significant and likely to be in the region of $70M or more. For this reason, all the currently used WHOPES recommended adulticides started their lives off as ag chem products -it is unfortunate that companies simply cannot justify the development costs for an insecticide solely for use in vector control.
Against this background the hurdles to developing a novel insecticide have grown ever higher, partly in the search for new modes of action chemistry that are currently not resisted and partly as a result of having a more stringent regulatory environment, which has resulted in higher thresholds for new chemistry and also the withdrawal of older chemistry. More compounds, therefore, have to be screened before a "hit" is identified -an estimated 140,000 molecules for every "hit" (Phillips MacDougall, 2010) . The overall impact is a higher cost of market entry, and fewer molecules being available for potential vector control applications.
With the lead time from initial discovery to first commercialisation now at approximately 10 years companies typically have less than 10 more years left to recoup the significant development costs before the patent expires and the product becomes available generically from companies which carry no basic research costs. As a general strategy, product development and marketing efforts behind new chemistry are directed at more profitable areas first -so patent cover has often expired by the time these molecules are formulated and marketed for vector control.
Associated with the dramatically increased regulatory costs, there has been a precipitous decline in the number of basic (i.e. non-generic) crop protection companies -I have witnessed some of this decline first hand, starting my career in the Pesticides R and D Division of the Wellcome Foundation in 1983. Over the next 30 years, through various mergers and acquisitions I have ended up working for a total of 5 separate companies. With the exception of Aventis (which no longer has an insecticide business) and Sumitomo Chemical (my present employer), none of the others still exist -companies with names like Wellcome Environmental Health, AgrEvo, Rhone Poulenc, Hoechst, Camco, Shell and Rousell Uclaf have all either been taken over or merged, or abandoned their insecticide development pipelines. There are now less than 10 primary submitter (in other words non-generic) companies with products in WHOPESand of these only a pitifully small handful -around half -are actively involved in the synthesis of new active ingredients with application in vector control. If this trend continues then will any basic manufacturers be left? Where will the new innovative products come from? Certainly not generic producers.
Luckily some help is at hand -the Innovative Vector Control Consortium, that receives financial backing from Gates, DFID, PMI and other sources, is a Public/Private development partnership that provides support and funding to help industry overcome the lack of commercial incentive to develop new vector control insecticides. However, even with this much needed support there is a limited budget available. For more information see http://www.ivcc.com/. The goal of these partners is to have new insecticides available in the vector control market by 2022.
That is the good news; the bad news is that there are still significant hurdles that threaten the future of our industry. For example, there is a process that allows companies to copy or "me too" existing WHOPES recommended products providing they can produce minimal data to show these are biologically and chemically equivalent to already recommended products. This saves the 'me too' applicant significant time and cost at minimal risk (for example, for an LN it can take a primary submitter 5 years and approximately $5 million in in-house development costs and a further $1 million to cover the costs of the WHOPES evaluation process to obtain a full WHOPES recommendation. A 'me-too' applicant by comparison has much smaller development costs, minimal risk of failure and can obtain a WHOPES recommendation through the equivalence process for approximately $50K in upfront costs to WHOPES -typically within a year or two. This clearly has an impact on the primary submitter's opportunity to obtain a return on investment and seriously dampens the enthusiasm to come up with innovative products -imagine the impact on innovation if patent life were reduced to one or two years! With the spread of resistance and the risk that our existing vector control insecticides, many of which have been with us for over 30 years, may start to fail, we should be doing all we can to encourage -not discourage -the already dwindling number of companies to invest in new, innovative and life saving technologies.
The problem is particularly acute where novel types of intervention are being developed which have modes of action that are not covered by the current WHOPES test guidelines. These novel approaches to insect control require more extensive, and much more expensive, proof of principle epidemiological studies before they will be endorsed by WHO. This is understandable as these are products that deliver a health care benefit whose epidemiological effect needs to be fully validated. So companies wishing to develop and market such novel products need to embark on long term and extremely costly multi-country epidemiological studies in order to demonstrate proof of principle. For the reasons noted above it is more than likely that the insecticides used for vector control will have been developed for ag use and are nearing or have reached the end of their patent life. With the current WHOPES equivalence process in place it is perhaps not surprising that many R and D based innovator companies are hesitant about making significant investments in this area, denying some of the world's most needy people potential life-saving technology.
One simple and much fairer solution would be for WHOPES to allow primary submitters a time limited protection of the data generated to support a recommendation, or alternatively an exclusive use period, sufficient to allow a return on their initial investment, providing they met certain criteria -such as committing to go to scale rapidly. After this period generic "me too" manufacturers would be allowed to come into the market, as long as their products were able to demonstrate exact equivalence. This would then act as an incentive for companies to innovate, develop and market new products around the new chemistry that hopefully will be available in the next 5 to 10 years.
If the key stakeholders do not recognise the problems outlined above, our industry will continue to contract and the notable gains made in recent years in reducing the impact of vectors in disease transmission could well be lost.
John Lucas *A WHOPEs recommendation is absolutely essential as donors and institutional buyers (who procure a significant proportion of the global bed net and indoor residual spray market) typically only procure products that carry a WHOPES recommendation.
